Immutep (ASX:IMM) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Dividend Payout Ratio?

Immutep's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Immutep's Dividend Payout Ratio or its related term are showing as below:

ASX:IMM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-06), the Dividend Yield % of Immutep is 0.00%.

Immutep's Dividends per Share for the months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Immutep Dividend Payout Ratio Historical Data

The historical data trend for Immutep's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Dividend Payout Ratio Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Dividend Payout Ratio

Get a 7-Day Free Trial

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immutep's Dividend Payout Ratio

For the Biotechnology subindustry, Immutep's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Immutep's Dividend Payout Ratio falls into.

Immutep Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Immutep's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2023 )	/	EPS without NRI (A: Jun. 2023 )
	=	0	/	-0.045
	=	N/A

Immutep's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

Immutep (ASX:IMM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Immutep Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Immutep's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (ASX:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines